Interpace Biosciences, Inc.
Interpace Biosciences, Inc. is a U.S.-based clinical diagnostics company that develops and performs proprietary molecular tests used to support cancer-related decision-making, with a focus on pancreatic and other oncology-related conditions. The company generates revenue primarily from clinical services billed to third-party payers and Medicare, and its business model is tightly linked to reimbursement coverage and laboratory test volumes.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueProprietary laboratory assays and molecular tests performed on patient specimens.
Customers
The company sells its clinical services into the healthcare reimbursement system, so its direct customers are largely physicians, hospitals, and other ordering providers that submit patient specimens for testing. Payment is typically collected from Medicare, commercial insurers, and other third-party payers, making reimbursement policy a central driver of demand and revenue realization.
They order proprietary tests to support diagnosis and treatment decisions, especially in oncology and pancreatic disease.
A key payer base for PancraGEN® and related testing; reimbursement coverage directly determines whether the test can be offered.
They reimburse clinical services and affect realized revenue through coverage policies and collection rates.
They submit specimens and rely on the company’s lab results to support patient management.
Strategy
Management is focused on preserving liquidity, improving margins, and resizing the cost base after the loss of Medicare reimbursement for PancraGEN®. The company is also pursuing strategic alternatives and financing options, while considering an uplisting to Nasdaq to improve access to capital.
The loss of PancraGEN® reimbursement requires a smaller operating footprint to preserve profitability and cash.
The company needs sufficient cash to fund operations while reimbursement and revenue visibility remain uncertain.
Future growth depends on sustaining clinical service revenue and developing new molecular solutions.
Geography
Interpace Biosciences operates as a U.S.-centric diagnostics business, with revenue driven by domestic clinical testing and U.S. reimbursement systems. The company’s exposure is concentrated in the United States because Medicare coverage decisions and U.S. laboratory regulations directly affect whether its tests can be marketed and reimbursed.
Risks
The most important company-specific risk is reimbursement dependence: CMS ended coverage for PancraGEN®, which materially reduces the company’s ability to sell that test and pressures revenue. The company also faces liquidity and refinancing risk because it has a secured lender with foreclosure rights and limited access to capital after its Nasdaq delisting, alongside typical diagnostics risks such as regulatory change, payer mix volatility, and third-party supply dependence.
The company states it cannot continue offering the test after CMS ended coverage, removing a core product from its portfolio.
Exposure: PancraGEN® and first-line fluid chemistry testing
The company relies on cash, collections, and external financing, but capital access is limited after delisting.
Exposure: Working capital and future growth funding
If obligations are not repaid on time, substantially all assets could be foreclosed upon.
Exposure: Asset base and going-concern flexibility
LDT oversight, payer coverage, and pricing rules can alter whether tests are reimbursed profitably.
Exposure: U.S. clinical diagnostics operations
The company depends on external suppliers for materials used in testing, which can affect service continuity.
Exposure: Laboratory consumables and test inputs
Accounting
Judgemental itemsRevenue is recorded using expected collection rates, so changes in payer behavior can affect reported sales.
Impact: Can shift revenue and gross margin between periods
Different payer categories have different collection patterns and reimbursement rates.
Impact: Affects net revenue and receivables valuation
The 2025 restructuring plan creates near-term charges tied to workforce reductions.
Impact: Impacts operating expenses and cash outflows
Equity awards are a recurring non-cash expense and part of critical accounting policies.
Impact: Affects operating income and adjusted EBITDA reconciliation
Similar listed companies
Publicly listed companies with a comparable business focus.
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Precigen, Inc
PGEN · Pharmaceutical Preparations
Erasca, Inc.
ERAS · Pharmaceutical Preparations
PharmaCyte Biotech, Inc.
PMCB · Biological Products, (No Diagnostic Substances)
Immuneering Corp
IMRX · Pharmaceutical Preparations
Immuneering Corp is a clinical-stage biotechnology company focused on developing oncology therapies, with an emphasis on MAPK pathway cancers and biomarker-driven patient selection.
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Last updated: 24/09/2026